Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

c. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that the company may experience delays in clinical trial patient enrollment, the results of future clinical trials may not correlate with the results from prior clinical and preclinical studies, the risk that the rate of objective tumor response for the expansion stages of the company's three Phase II trials will not be consistent with the objective tumor responses experienced in the first stage of the respective Phase II trials, the risk that the standard chemotherapy response rate will not be improved as a result of the combination therapy with the inclusion of bavituximab, the risk that the company will not be able to raise additional capital under its "At the Market" sales agreement, the risk that Avid's revenue growth may slow or decline, the risk that Avid may experience technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, the risk that one or more existing Avid customers terminates its contract prior to completion, the risk that the company does not receive all of its funding under the DTRA contract, the risk that future protocol submissions may not be approved and the risk that the co
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Deep Market Research Report ... and in-depth study on the current state of ... a focus on the Chinese situation. , Major ... Wuhan Youji, Tongtai, Tenlong, Zhiyuan, MILAN, Dongda, Fengkang, ... W.ULRICH. , The report provides a basic overview ...
(Date:2/26/2015)... In this episode of SCI TV , ... her study that searched for commonalities in the stories ... Field. Shadle wanted to explore the key factors, beyond ... success and helped win the Olympic gold. The mental ... to peak athletic performance but to any major life ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... Hair Restoration have monitored the evolution of one of ... The ARTAS system offers a machinery ... with accuracy from the patient’s scalp,” said Dr. Parsa ... FUE grafts automated, the speed at which the device ...
(Date:2/26/2015)... Reno, Nevada (PRWEB) February 26, 2015 Imagine ... were no showers or proper baths and there was no ... the world, that day was today. In 2015, more than ... in the developing world. , A new initiative led ... to dramatically reduce those numbers, focusing specifically on women – ...
(Date:2/26/2015)... Atlanta, GA (PRWEB) February 26, 2015 ... 2015 Movers & Makers Awards finalist. ... of exceptional companies involved in the manufacturing, processing, or distribution ... at the Gwinnett Center. This annual event serves as ... companies and is expected to draw more than 300 local ...
Breaking Medicine News(10 mins):Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 2Health News:Global Sodium Benzoate Industry Analysis Report 2015-2020 Now at DeepResearchReports.com 3Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 2Health News:Anne Shadle and Controlling the Olympic Moment on SCI TV 3Health News:Newest Technology now Available at Parsa Mohebi Hair Restoration 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 2Health News:DRI launches Global Initiative to Provide Women in Developing Countries with Clean Water 3Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3
... world's most common liver infection. It spreads easily and is ... ,It causes liver cirrhosis, // liver failure and liver cancer. ... the world's population, has been infected with the hepatitis B ... chronic carriers of the virus. Normally in case of adults ...
... Alcohol consumption is related to liver malfunction and now it ... by French scientists it has been found that alcohol consumption ... for many types of cancer., ,Scientists found that excessive ... liver, colon and breast. ,As mentioned on the ...
... (CWD) is widespread in Alberta.,Acadia Valley is the province which ... 837 wild deer have been culled to prevent the spread ... the government to take necessary steps to stop the spread ... new cases were detected among the culled deer. ...
... sleep for several days at a stretch with the development of ... ,The ‘24-hour lifestyle’ pills currently under development may allow people ... ,The pill promises to deliver sleep that is deeper and more ... sleep for days, reported online edition of The New Scientist. The ...
... targets for health services were meant to motivate health care ... improvement in Healthcare. According to researchers, these // ... to keep manipulation tactics at bay. ,Gwyn Bevan ... indeed lauded the target based assessment, but have gone further ...
... oxygen supplies are facing a setback, after four private companies ... in February, this year. This has created huge problems for ... life and death. //It is estimated that about 60,000 people ... threatening problems. ,Home deliveries of Oxygen have ...
Cached Medicine News:
(Date:2/26/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), ... therapies for cancer, announced today that Daniel P. Gold ... the Cowen and Company 35 th Annual Health Care ... time from the Boston Marriott Copley Place. A live webcast ... A replay will be available approximately one hour after the ...
(Date:2/26/2015)... , February 26, 2015 ABIVAX, a ... human vaccines, today announced that it has dosed in ... Phase IIb/III clinical trial of ABX203 which is taking place ... region. The study is designed to assess whether ABX203 can ... B (CHB) via controlling viral load for a much longer ...
(Date:2/26/2015)... Feb. 26, 2015 ANSYS (NASDAQ: ... manufacturer of diesel engines and global power leader, Cummins ... broad access to the ANSYS ® portfolio. This ... solve some of the industry,s most challenging multiphysics problems ... innovative products on the market. The multi-year ...
Breaking Medicine Technology:MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Cummins Standardizes On ANSYS Engineering Simulation Software 2Cummins Standardizes On ANSYS Engineering Simulation Software 3
Slick® Disposable Endotracheal Stylet, Nylon-coated wire, Malleable core, Sureloc Stop helps maintain desired length for patient safety. Handle forming capability for better grip. Sterile. Single...
... spine manipulation. Prevent dental and soft tissue ... alternative to X-ray. Light-guided intubation is based ... in the neck. This technique takes advantage ... relative to the esophagus. A well-defined, circumscribed ...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
... of flexible lighting products. The first is ... different sizes 5", 10", and 15" (refers ... light). These lights are for use in ... ,The second group of flexible lights is ...
Medicine Products: